Evaluation of eltrombopag in patients with aplastic anemia in real-world experience.
Aplastic anemia
Eltrombopag
Neutrophil-to-lymphocyte ratio
Real-world setting
Journal
Leukemia research reports
ISSN: 2213-0489
Titre abrégé: Leuk Res Rep
Pays: England
ID NLM: 101608906
Informations de publication
Date de publication:
2019
2019
Historique:
received:
05
01
2019
revised:
24
02
2019
accepted:
03
03
2019
entrez:
27
3
2019
pubmed:
27
3
2019
medline:
27
3
2019
Statut:
epublish
Résumé
Although eltrombopag has recently been approved for treating AA, the effects of its clinical use remain unknown. We retrospectively analyzed 11 patients with AA, who had been treated with eltrombopag from August 2017 to May 2018. Overall response rate was 55%. There was tri-lineage recovery in four patients and platelet recovery in two. The reactive time was within 8 weeks after treatment initiation. Stage at the initial assessment, the neutrophil-to-lymphocyte ratio and platelet counts were significantly different between the responders and non-responders. Eltrombopag is a promising agent for treating patients with any degree of AA.
Sections du résumé
BACKGROUND
BACKGROUND
Although eltrombopag has recently been approved for treating AA, the effects of its clinical use remain unknown.
METHODS
METHODS
We retrospectively analyzed 11 patients with AA, who had been treated with eltrombopag from August 2017 to May 2018.
RESULTS
RESULTS
Overall response rate was 55%. There was tri-lineage recovery in four patients and platelet recovery in two. The reactive time was within 8 weeks after treatment initiation. Stage at the initial assessment, the neutrophil-to-lymphocyte ratio and platelet counts were significantly different between the responders and non-responders.
CONCLUSION
CONCLUSIONS
Eltrombopag is a promising agent for treating patients with any degree of AA.
Identifiants
pubmed: 30911464
doi: 10.1016/j.lrr.2019.03.002
pii: S2213-0489(19)30003-2
pmc: PMC6416522
doi:
Types de publication
Journal Article
Langues
eng
Pagination
11-13Références
Blood. 2006 Oct 15;108(8):2509-19
pubmed: 16778145
Blood. 2007 Sep 1;110(5):1603-6
pubmed: 17463169
N Engl J Med. 2012 Jul 5;367(1):11-9
pubmed: 22762314
Bone Marrow Transplant. 2013 Mar;48(3):452-8
pubmed: 23208313
Hematology Am Soc Hematol Educ Program. 2013;2013:87-94
pubmed: 24319168
Blood. 2014 Mar 20;123(12):1818-25
pubmed: 24345753
Haematologica. 2014 Dec;99(12):1784-91
pubmed: 25193958
N Engl J Med. 2017 Apr 20;376(16):1540-1550
pubmed: 28423296
Haematologica. 2018 Feb;103(2):212-220
pubmed: 29170252
Br J Haematol. 1988 Oct;70(2):177-82
pubmed: 3056497